JP2021048806A - Melatonin production promoter and sleep quality improver - Google Patents
Melatonin production promoter and sleep quality improver Download PDFInfo
- Publication number
- JP2021048806A JP2021048806A JP2019175044A JP2019175044A JP2021048806A JP 2021048806 A JP2021048806 A JP 2021048806A JP 2019175044 A JP2019175044 A JP 2019175044A JP 2019175044 A JP2019175044 A JP 2019175044A JP 2021048806 A JP2021048806 A JP 2021048806A
- Authority
- JP
- Japan
- Prior art keywords
- sulforaphane
- glucoraphanin
- sleep quality
- melatonin production
- food composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 51
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229960003987 melatonin Drugs 0.000 title claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 43
- 230000003860 sleep quality Effects 0.000 title claims abstract description 32
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims abstract description 130
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims abstract description 65
- 229960005559 sulforaphane Drugs 0.000 claims abstract description 65
- 235000015487 sulforaphane Nutrition 0.000 claims abstract description 65
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 claims abstract description 59
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 claims abstract description 59
- 230000001737 promoting effect Effects 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 32
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 29
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 29
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 28
- 241000196324 Embryophyta Species 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 description 24
- 230000037406 food intake Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- -1 gummy Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 108010058651 thioglucosidase Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 240000007124 Brassica oleracea Species 0.000 description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000004383 glucosinolate group Chemical group 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 241000219198 Brassica Species 0.000 description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
- 241000219193 Brassicaceae Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940044613 1-propanol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000008537 Brassica juncea var. integrifolia Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 244000117494 takana Species 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明が関係するのは、メラトニン産生促進剤及び睡眠の質改善剤、並びに、メラトニン産生促進用食品組成物及び睡眠の質改善用食品組成物である。 The present invention relates to a melatonin production promoter and a sleep quality improving agent, and a melatonin production promoting food composition and a sleep quality improving food composition.
睡眠は食や運動と同様に健康長寿に影響する重要な因子である。一方で、現代社会においては、生活リズムの乱れやストレス、運動不足等により睡眠不足、不眠等の症状を訴える人が多く存在する。睡眠の質の低下は、心筋梗塞や脳梗塞等の重大な疾患に繋がるだけでなく、日中の眠気から作業能率が低下し、重大な事故を誘発する可能性があり、睡眠の質を改善することは重要な課題である。 Sleep is as important a factor in affecting health and longevity as it is in eating and exercising. On the other hand, in modern society, there are many people who complain of sleep deprivation, insomnia, etc. due to disturbance of life rhythm, stress, lack of exercise, etc. Poor sleep quality not only leads to serious illnesses such as myocardial infarction and cerebral infarction, but also improves work efficiency due to daytime sleepiness, which can lead to serious accidents and improve sleep quality. To do is an important task.
睡眠の質の低下は、一般的に、寝つきが悪い入眠障害、夜中に何度も目が覚める中途覚醒、朝早くに目が覚めてしまう早期覚醒、よく眠った感じがしない熟眠不全等に分類される。これらの症状に対する治療法としては、ベンゾジアゼピン系や抗ヒスタミン系等の睡眠改善医薬品による薬物療法が挙げられる。これらの医薬品は、睡眠改善効果を有するが、精神症状や筋弛緩作用などの副作用があり、医薬品であるため、簡便に入手できない。 Poor sleep quality is generally categorized as difficulty falling asleep, difficulty falling asleep, awakening during the night, early awakening that wakes up early in the morning, and deep sleep insufficiency that does not make you feel well asleep. Will be done. Treatment methods for these symptoms include drug therapy with sleep-improving drugs such as benzodiazepines and antihistamines. Although these drugs have a sleep improving effect, they have side effects such as psychiatric symptoms and muscle relaxant action, and since they are drugs, they cannot be easily obtained.
これまでに、睡眠改善効果を有する成分として、テアニン（特許文献１）、グリシン（特許文献２）、オルニチン（特許文献３）、γ−アミノ酪酸（特許文献４）等が開示されている。 So far, theanine (Patent Document 1), glycine (Patent Document 2), ornithine (Patent Document 3), γ-aminobutyric acid (Patent Document 4) and the like have been disclosed as components having a sleep improving effect.
一方、ブロッコリー等のアブラナ科の植物には、スルフォラファンの前駆体グルコラファニンが多く含まれ、当該植物の組織中に含まれるグルコラファニンは、組織が破壊されると内在性の酵素ミロシナーゼにより加水分解され、スルフォラファンを生じることが知られている（非特許文献１）。また、グルコラファニンを摂取した場合においても、腸内細菌によってスルフォラファンに変換されて腸管から吸収されることが知られている。スルフォラファン及びその前駆体グルコシノレートであるグルコラファニンには、第二相解毒酵素を誘導する作用等が知られているが、メラトニンの産生及び睡眠に対する作用効果はこれまでに知られていなかった。 On the other hand, cruciferous plants such as broccoli contain a large amount of sulforaphane precursor glucoraphanin, and glucoraphanin contained in the tissue of the plant is hydrated by the endogenous enzyme myrosinase when the tissue is destroyed. It is known that it is decomposed to produce sulforaphane (Non-Patent Document 1). It is also known that when glucoraphanin is ingested, it is converted to sulforaphane by intestinal bacteria and absorbed from the intestinal tract. Sulforaphane and its precursor glucosinolate, glucosinolate, are known to have an action of inducing a phase II detoxifying enzyme, but the action effect on melatonin production and sleep has not been known so far. ..
本発明が解決しようとする課題は、安全性が高く、長期に適用可能なメラトニン産生促進剤を提供することである。 An object to be solved by the present invention is to provide a melatonin production promoter which is highly safe and can be applied for a long period of time.
以上を踏まえて、本願発明者が鋭意検討して見出したのは、グルコラファニン及びスルフォラファンの少なくとも１種によるメラトニン産生促進機能、及び、それによる睡眠の質改善機能である。すなわち、グルコラファニン及びスルフォラファンの少なくとも一種の作用により、メラトニン産生が促進され、睡眠の質が改善される。この観点から、本発明を定義すると、以下のとおりである。 Based on the above, the inventor of the present application has diligently studied and found a function of promoting melatonin production by at least one of glucoraphanin and sulforaphane, and a function of improving sleep quality by the function. That is, at least one action of glucoraphanin and sulforaphane promotes melatonin production and improves sleep quality. From this point of view, the present invention is defined as follows.
本発明に係るメラトニン産生促進剤の有効成分は、グルコラファニン及びスルフォラファンの少なくとも一種である。ここで、グルコラファニン及びスルフォラファンはアブラナ科植物由来であり、ブロッコリー由来であることが好ましく、ブロッコリースプラウト抽出物の形態であることがより好ましい。 The active ingredient of the melatonin production promoter according to the present invention is at least one of glucoraphanin and sulforaphane. Here, glucoraphanin and sulforaphane are derived from cruciferous plants, preferably derived from broccoli, and more preferably in the form of broccoli sprout extract.
本発明に係るメラトニン産生促進用食品組成物が含有するのは、少なくとも、グルコラファニン及びスルフォラファンの少なくとも一種である。ここで、グルコラファニン及びスルフォラファンはアブラナ科植物由来であり、ブロッコリー由来であることが好ましく、ブロッコリースプラウト抽出物の形態であることがより好ましい。言い換えると、当該メラトニン産生促進用食品組成物の機能性成分は、少なくとも、グルコラファニン及びスルフォラファンの少なくとも一種である。 The food composition for promoting melatonin production according to the present invention contains at least one of glucoraphanin and sulforaphane. Here, glucoraphanin and sulforaphane are derived from cruciferous plants, preferably derived from broccoli, and more preferably in the form of broccoli sprout extract. In other words, the functional component of the melatonin production promoting food composition is at least one of glucoraphanin and sulforaphane.
本発明に係る睡眠の質改善剤の有効成分は、グルコラファニン及びスルフォラファンの少なくとも一種である。ここで、グルコラファニン及びスルフォラファンはアブラナ科植物由来であり、ブロッコリー由来であることが好ましく、ブロッコリースプラウト抽出物の形態であることがより好ましい。 The active ingredient of the sleep quality improving agent according to the present invention is at least one of glucoraphanin and sulforaphane. Here, glucoraphanin and sulforaphane are derived from cruciferous plants, preferably derived from broccoli, and more preferably in the form of broccoli sprout extract.
本発明に係る睡眠の質改善用食品組成物が含有するのは、少なくとも、グルコラファニン及びスルフォラファンの少なくとも一種である。ここで、グルコラファニン及びスルフォラファンはアブラナ科植物由来であり、ブロッコリー由来であることが好ましく、ブロッコリースプラウト抽出物の形態であることがより好ましい。 The food composition for improving sleep quality according to the present invention contains at least one of glucoraphanin and sulforaphane. Here, glucoraphanin and sulforaphane are derived from cruciferous plants, preferably derived from broccoli, and more preferably in the form of broccoli sprout extract.
本発明が可能にするのは、安全性が高く、長期に適用可能なメラトニン産生促進剤である。すなわち、グルコラファニン及びスルフォラファンは、ブロッコリーやケール等の食経験の豊富な植物から容易に取得可能であり、長期投与又は摂取が可能である。さらに、グルコラファニン及びスルフォラファンの少なくとも一種の作用により、メラトニンの産生が促進されることで、睡眠の質改善効果が奏される。 The present invention enables a melatonin production promoter that is highly safe and can be applied for a long period of time. That is, glucoraphanin and sulforaphane can be easily obtained from plants with abundant eating experience such as broccoli and kale, and can be administered or ingested for a long period of time. Furthermore, the action of at least one of glucoraphanin and sulforaphane promotes the production of melatonin, thereby producing an effect of improving sleep quality.
＜メラトニン産生促進剤＞
本発明に係るメラトニン産生促進剤は、有効成分としてグルコラファニン及びスルフォラファンの少なくとも一種を含有する。グルコラファニン及びスルフォラファンは、好ましくは植物由来であり、ブロッコリースプラウト由来であることがより好ましい。メラトニン産生促進剤の詳細は、後述する。
<Melatonin production promoter>
The melatonin production promoter according to the present invention contains at least one of glucoraphanin and sulforaphane as active ingredients. Glucoraphanin and sulforaphane are preferably derived from plants, more preferably from broccoli sprout. Details of the melatonin production promoter will be described later.
＜メラトニン産生促進用食品組成物＞
本発明に係るメラトニン産生促進用食品組成物は、グルコラファニン及びスルフォラファンの少なくとも一種を含有する。グルコラファニン及びスルフォラファンは、好ましくは植物由来であり、ブロッコリースプラウト由来であることがより好ましい。メラトニン産生促進用食品組成物の詳細は、後述する。
<Food composition for promoting melatonin production>
The food composition for promoting melatonin production according to the present invention contains at least one of glucoraphanin and sulforaphane. Glucoraphanin and sulforaphane are preferably derived from plants, more preferably from broccoli sprout. Details of the food composition for promoting melatonin production will be described later.
＜グルコラファニン及びスルフォラファン＞
グルコラファニンは、グルコシノレートの１種であり、スルフォラファンの前駆体である。酵素ミロシナーゼにより加水分解され、スルフォラファンとなる。また、ヒト等の哺乳動物がグルコラファニンを摂取した場合においても、スルフォラファンに変換されて腸管から吸収される。グルコラファニンはアブラナ科植物に多く含有されていることが知られており、本発明において、グルコラファニンは、精製された状態で剤や飲食品に含有されていてもよく、アブラナ科植物、その抽出物又はその分画、及びその粉砕物から選択される一以上の状態で含有されてもよい。
<Glucoraphanin and sulforaphane>
Glucoraphanin is a type of glucosinolate and is a precursor of sulforaphane. It is hydrolyzed by the enzyme myrosinase to sulforaphane. In addition, even when a mammal such as a human ingests glucoraphanin, it is converted to sulforaphane and absorbed from the intestinal tract. It is known that glucoraphanin is abundantly contained in cruciferous plants, and in the present invention, glucoraphanin may be contained in agents and foods and drinks in a purified state, and cruciferous plants, It may be contained in one or more states selected from the extract or fraction thereof and the ground product thereof.
＜アブラナ科植物＞
アブラナ科植物は、特に限定されないが、例示すると、ブロッコリー、ケール、キャベツ、カリフラワー、高菜、アブラナ、カラシナ、大根、大根葉、野沢菜、小松菜、白菜、芽キャベツ、プチヴェール、及び、これらを適宜交配して作製した植物が挙げられる。植物体の部分としては、植物の成長体（芽、葉、茎、根、又は花など）でも、スプラウト（発芽体）でも、種子でもよく、特に制限されない。これらのうちより好ましいのは、アブラナ科アブラナ属に属するブロッコリーである。さらに、グルコラファニン及びスルフォラファンの少なくとも一種の含量の高さから、ブロッコリーのスプラウト又は種子が特に好ましい。
<Brassicaceae>
The cruciferous plants are not particularly limited, but for example, broccoli, kale, cabbage, cauliflower, takana, abrana, mustard, radish, radish leaf, nozawa greens, komatsuna, white vegetables, Brussels sprouts, petit veil, and these are appropriately crossed. Examples of plants produced in the above. The part of the plant body may be a growing body of a plant (bud, leaf, stem, root, or flower, etc.), a sprout (germinated body), or a seed, and is not particularly limited. More preferred of these are broccoli belonging to the Brassicaceae genus Brassica. In addition, broccoli sprouts or seeds are particularly preferred due to their high content of at least one of glucoraphanin and sulforaphane.
＜ブロッコリースプラウト抽出物＞
ブロッコリースプラウトからグルコラファニン及びスルフォラファンの少なくとも一種を抽出する場合は、その含有量が減少傾向になる成長体になる前であれば発芽後何日後であってもよいが、好ましくは、発芽と１〜１０日後、より好ましくは１〜３日後のスプラウトを用いることである。また、グルコラファニン及びスルフォラファンの少なくとも一種の含有量が、好ましくは、５０〜３５０ｍｇ／１００ｇ（湿重量）、より好ましくは１５０〜３３０ｍｇ／１００ｇ（湿重量）、さらに好ましくは、２５０〜３００ｍｇ／１００ｇ（湿重量）のブロッコリースプラウトを用いることである。
<Broccoli sprout extract>
When at least one of glucoraphanin and sulforaphane is extracted from broccoli sprout, it may be several days after germination as long as it is before the growth body whose content tends to decrease, but preferably germination and 1 It is to use the sprout after 10 days, more preferably 1 to 3 days. The content of at least one of glucoraphanin and sulforaphane is preferably 50 to 350 mg / 100 g (wet weight), more preferably 150 to 330 mg / 100 g (wet weight), and even more preferably 250 to 300 mg / 100 g. Use a (wet weight) broccoli sprout.
＜グルコラファニン及びスルフォラファンの取得＞
ブロッコリースプラウト等を含むアブラナ科植物からのグルコラファニン及びスルフォラファンの少なくとも一種の取得は、周知の方法により行うことができる。また、単離精製されたグルコラファニン及びスルフォラファンは市販されており、当該市販品を使用することもできる。
<Acquisition of glucoraphanin and sulforaphane>
At least one of glucoraphanin and sulforaphane can be obtained from cruciferous plants including broccoli sprout and the like by a well-known method. In addition, isolated and purified glucoraphanin and sulforaphane are commercially available, and the commercially available products can also be used.
＜植物からの抽出＞
例えば、グルコラファニンは、植物の一部または全体をそのまま又は乾燥粉砕したものを溶媒等で抽出して取得することができ、溶媒としては、水、低級１価アルコール（メタノール、エタノール、１−プロパノール、２−プロパノール、１−ブタノール、２−ブタノール等）、液状多価アルコール（グリセリン、プロピレングリコール、１，３−ブチレングリコール等）、低級エステル（酢酸エチル等）、炭化水素（ベンゼン、ヘキサン、ペンタン等）、ケトン類（アセトン、メチルエチルケトン等）、エーテル類（ジエチルエーテル、テトラヒドロフラン、ジプロピルエーテル等）、アセトニトリル等が挙げられ、それらの一種又は２種以上を用いることができる。
<Extraction from plants>
For example, glucorafanine can be obtained by extracting a part or the whole of a plant as it is or by drying and pulverizing it with a solvent or the like, and as the solvent, water or a lower monohydric alcohol (methanol, ethanol, 1- Propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (glycerin, propylene glycol, 1,3-butylene glycol, etc.), lower esters (ethyl acetate, etc.), hydrocarbons (benzene, hexane, etc.) Pentan and the like), ketones (acetone, methyl ethyl ketone and the like), ethers (diethyl ether, tetrahydrofuran, dipropyl ether and the like), acetonitrile and the like can be mentioned, and one or more of them can be used.
本発明の剤又は食品組成物は経口で投与又は摂取されることを考慮すると、抽出溶媒としては、水、エタノール、又は含水エタノールが特に好ましい。好ましい抽出方法の例としては、例えば熱水（９０〜１００℃）で、１０〜３０分間抽出する方法や、０〜１００体積％の含水エタノールで室温又は加温して１〜１０日間抽出する方法が挙げられ、その抽出液をさらに分画・精製してもよい。その他に、超臨界抽出によってグルコラファニンを抽出してもよい。 Considering that the agent or food composition of the present invention is orally administered or ingested, water, ethanol, or hydrous ethanol is particularly preferable as the extraction solvent. Examples of preferable extraction methods include, for example, a method of extracting with hot water (90 to 100 ° C.) for 10 to 30 minutes, and a method of extracting at room temperature or heating with 0 to 100% by volume of hydrous ethanol for 1 to 10 days. The extract may be further fractionated and purified. Alternatively, glucoraphanin may be extracted by supercritical extraction.
＜グルコラファニンからスルフォラファンを得る方法＞
グルコラファニンからスルフォラファンを得る方法としては、グルコラファニンとミロシナーゼを反応させればよく、その方法は限定されない。例えば、グルコラファニンを含むアブラナ科植物を、加熱せずに破砕、摩砕、粉砕、せん断、搾汁等することでグルコラファニンと内在のミロシナーゼを反応させ、スルフォラファンに代謝させる方法や、グルコラファニンにミロシナーゼを添加してスルフォラファンに代謝させる方法等が挙げられる。スルフォラファンは、これらの方法にてグルコラファニンから代謝されたスルフォラファンを含む原料から、グルコラファニンと同様の方法（例えば、前述の抽出等の方法）にて取得することができる。
<How to get sulforaphane from glucoraphanin>
The method for obtaining sulforaphane from glucoraphanin may be a reaction between glucoraphanin and myrosinase, and the method is not limited. For example, a method of reacting glucoraphanin with endogenous myrosinase by crushing, grinding, crushing, shearing, squeezing, etc. a cruciferous plant containing glucoraphanin without heating and metabolizing it to sulforaphane, or gluco Examples thereof include a method of adding myrosinase to raphanin and metabolizing it to sulforaphane. Sulforaphane can be obtained from a raw material containing sulforaphane metabolized from glucoraphanin by these methods by the same method as glucoraphanin (for example, the above-mentioned extraction method).
＜グルコラファニンの濃度測定＞
剤、食品組成物、又は抽出物等の中のグルコラファニンの濃度測定は、当業者周知の方法により行うことができる。例えば、高速液体クロマトグラフィー（ＨＰＬＣ）法を用いることができ、具体的な方法としては、Faheyらの方法（Fahey et al., Proc. Natl. Acad. Sci. USA, 94, 10367-10372, 1997）等に従って行うことができる。
<Measurement of glucoraphanin concentration>
The concentration of glucoraphanin in an agent, food composition, extract or the like can be measured by a method well known to those skilled in the art. For example, a high performance liquid chromatography (HPLC) method can be used, and specific methods include the method of Fahey et al., Proc. Natl. Acad. Sci. USA, 94, 10367-10372, 1997. ) Etc. can be performed.
＜スルフォラファンの濃度測定＞
剤、食品組成物、又は抽出物等の中のスルフォラファンの濃度測定は、当業者周知の方法により行うことができる。例えば、高速液体クロマトグラフィー（ＨＰＬＣ）法を用いることができ、具体的な方法としては、Hanらの方法（Han et al., Int. J. Mol. Sci., 12, 1854-1861, 2011）等に従って行うことができる。
<Measurement of sulforaphane concentration>
The concentration of sulforaphane in an agent, food composition, extract or the like can be measured by a method well known to those skilled in the art. For example, a high performance liquid chromatography (HPLC) method can be used, and specific methods include the method of Han et al. (Han et al., Int. J. Mol. Sci., 12, 1854-1861, 2011). Etc. can be performed.
＜メラトニン産生促進剤＞
本発明のメラトニン産生促進剤の投与形態としては、例えば、錠剤、被覆錠剤、カプセル剤、顆粒剤、散剤、溶液、シロップ剤、乳液等による経口投与を好ましく挙げることができる。なお、非経口投与形態が排除されるわけではなく、局所組織投与や、注射による皮下、皮内、筋肉内、静脈内投与、或いは、有効成分を揮発させることによる鼻腔内投与等によってもよい。
<Melatonin production promoter>
As the administration form of the melatonin production promoter of the present invention, for example, oral administration with tablets, coated tablets, capsules, granules, powders, solutions, syrups, emulsions and the like can be preferably mentioned. The parenteral administration form is not excluded, and may be administered by local tissue administration, subcutaneous, intradermal, intramuscular, intravenous administration by injection, intranasal administration by volatilizing the active ingredient, or the like.
本発明のメラトニン産生促進剤は、賦形剤、結合剤、崩壊剤、滑沢剤、着色剤、矯味矯臭剤、溶解補助剤、懸濁剤、コーティング剤などの医薬等の製剤技術分野において通常使用し得る既知の補助剤を用いて製剤化することができる。また、本発明のメラトニン産生促進剤の分類としては、医薬品または医薬部外品の態様であってもよい。 The melatonin production promoter of the present invention is usually used in the field of formulation technology such as pharmaceuticals such as excipients, binders, disintegrants, lubricants, colorants, flavoring agents, solubilizing agents, suspending agents and coating agents. It can be formulated with known adjuvants that may be used. In addition, the classification of the melatonin production promoter of the present invention may be in the form of a drug or a quasi-drug.
＜メラトニン産生促進用食品組成物＞
本発明のメラトニン産生促進用食品組成物としては、例えば、飲料（ジュース、コーヒー、紅茶、茶、炭酸飲料、スポーツ飲料、青汁等）、菓子類（ガム、キャンディー、キャラメル、チョコレート、クッキー、スナック、ゼリー、グミ、錠菓等）、麺類（そば、うどん、ラーメン等）、乳製品（ミルク、アイスクリーム、ヨーグルト等）、調味料（味噌、醤油等）、スープ類、をはじめとする一般食品や、健康食品（錠剤、カプセル等）、栄養補助食品（サプリメント、栄養ドリンク等）が挙げられる。
<Food composition for promoting melatonin production>
Examples of the food composition for promoting melatonin production of the present invention include beverages (juice, coffee, tea, tea, carbonated beverages, sports beverages, green juice, etc.) and confectionery (gum, candy, caramel, chocolate, cookies, snacks). , Jelly, gummy, tablet confectionery, etc.), noodles (soba, udon, ramen, etc.), dairy products (milk, ice cream, yogurt, etc.), seasonings (miso, soy sauce, etc.), soups, and other general foods , Health foods (tablets, capsules, etc.), dietary supplements (supplements, nutritional drinks, etc.).
これら食品組成物には、その種類に応じて種々の成分を配合することができ、例えば、ブドウ糖、果糖、ショ糖、マルトース、ソルビトール、コーンスターチ、デキストリン、ステビオサイド、コーンシロップ、乳糖、クエン酸、酒石酸、リンゴ酸、コハク酸、乳酸、Ｌ−アスコルビン酸、ｄｌ−α−トコフェロール、エリソルビン酸ナトリウム、グリセリン、プロピレングリコール、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステル、プロピレングリコール脂肪酸エステル、セルロース、アラビアガム、カラギーナン、カゼイン、ゼラチン、ペクチン、寒天、ビタミンＢ類、ニコチン酸アミド、パントテン酸カルシウム、アミノ酸類、カルシウム塩類、色素、香料、保存剤等の食品添加物を任意に使用することができる。 Various ingredients can be blended in these food compositions depending on the type, for example, glucose, fructose, sucrose, maltose, sorbitol, corn starch, dextrin, stebioside, corn syrup, lactose, citric acid, tartrate acid. , Malic acid, succinic acid, lactic acid, L-ascorbic acid, dl-α-tocopherol, sodium erythorbic acid, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid Optional use of food additives such as esters, cellulose, arabic gum, carrageenan, casein, gelatin, pectin, agar, vitamin Bs, malic acid amide, calcium pantothenate, amino acids, calcium salts, pigments, fragrances, preservatives, etc. can do.
＜グルコラファニン及びスルフォラファンの含有量＞
本発明のメラトニン産生促進剤は、特に限定されないが、グルコラファニン及びスルフォラファンの少なくとも一種を合計で０．０３質量％以上含有していることが好ましく、０．５質量％以上含有していることがより好ましく、５質量％以上含有していることが特に好ましい。
<Contents of glucoraphanin and sulforaphane>
The melatonin production promoter of the present invention is not particularly limited, but preferably contains at least one of glucoraphanin and sulforaphane in a total amount of 0.03% by mass or more, and preferably 0.5% by mass or more. Is more preferable, and it is particularly preferable that the content is 5% by mass or more.
また、本発明のメラトニン産生促進用食品組成物は、特に限定されないが、グルコラファニン及びスルフォラファンの少なくとも一種を合計で０．０１質量％以上含有していることが好ましく、０．０４質量％以上含有していることがより好ましく、０．２５質量％以上含有していることが特に好ましい。 The food composition for promoting melatonin production of the present invention is not particularly limited, but preferably contains at least one of glucoraphanin and sulforaphane in a total amount of 0.01% by mass or more, preferably 0.04% by mass or more. It is more preferable that it is contained, and it is particularly preferable that it is contained in an amount of 0.25% by mass or more.
＜投与量／摂取量＞
本発明のメラトニン産生促進剤の投与量、又はメラトニン産生促進用食品組成物の摂取量は、投与／摂取する対象がヒトである場合、その性別、症状、年齢、投与方法によって異なるが、グルコラファニン及びスルフォラファンの少なくとも一種が通常、成人（体重６０ｋｇ程度）１日当たり２４ｍｇ以上であればよく、３０ｍｇ以上であることが、作用が十分に発揮される観点から好ましい。この１日当たりの量を一度に又は数回に分けて投与／摂取することができ、そのタイミングとしては、食前、食後、食間のいずれでもよい。また、投与／摂取期間は特に限定されないが、４週間以上継続的に摂取することが好ましい。
<Dose / Intake>
The dose of the melatonin production-promoting agent of the present invention or the intake of the melatonin-promoting food composition varies depending on the sex, symptom, age, and administration method when the subject to be administered / ingested is human, but glucoraphane At least one of nin and sulforaphane usually needs to be 24 mg or more per day for an adult (body weight of about 60 kg), and 30 mg or more is preferable from the viewpoint of fully exerting the action. This daily amount can be administered / ingested at one time or in several divided doses, and the timing may be any of pre-meal, post-meal, and inter-meal. The administration / intake period is not particularly limited, but it is preferable to continuously ingest for 4 weeks or more.
なお、前述の１日当たりの投与量は、食品組成物の形態によって異なるが、表示される１日の摂取目安量や、通常１度で消費する飲みきりタイプの飲料であれば１本当たりに含まれる量を指すものである。 The above-mentioned daily dose varies depending on the form of the food composition, but it is included in the displayed daily intake guideline amount and in the case of a single-drink type beverage that is normally consumed at one time. It refers to the amount of food that is consumed.
＜睡眠の質改善剤及び睡眠の質改善用食品組成物＞
後述の実施例にて示される通り、本発明のメラトニン産生促進剤の作用により、睡眠の質が改善されると考えられる。ここで、「睡眠の質改善」とは、メラトニンが産生されることにより、例えば、概日リズム睡眠障害が予防される、寝付きが良くなる、深い眠りに入ることをいうが、これに限定されない。
<Sleep quality improver and sleep quality improving food composition>
As shown in Examples described later, it is considered that the quality of sleep is improved by the action of the melatonin production promoter of the present invention. Here, "improvement of sleep quality" means, for example, prevention of circadian rhythm sleep disorder, better sleep, and deep sleep due to the production of melatonin, but is not limited to this. ..
したがって、本発明の他の態様として、グルコラファニン及びスルフォラファンの少なくとも一種を有効成分として含有する、睡眠の質改善剤及び睡眠の質改善用食品組成物も提供される。 Therefore, as another aspect of the present invention, a sleep quality improving agent and a sleep quality improving food composition containing at least one of glucoraphanin and sulforaphane as active ingredients are also provided.
本発明の睡眠の質改善剤及び睡眠の質改善用食品組成物の寄与成分、投与量、態様等の具体的な説明については、前述したメラトニン産生促進剤及びメラトニン産生促進用の食品組成物の説明に準ずる。 For specific explanations of the contributing components, doses, aspects, etc. of the sleep quality improving agent and the food composition for improving sleep quality of the present invention, the above-mentioned melatonin production promoting agent and the food composition for promoting melatonin production are described. Follow the explanation.
本発明のメラトニン産生促進用食品組成物及び睡眠の質改善用食品組成物は、前述した機能性や生体に対する有用な作用に基づいて、好適に機能性表示食品や特定保健用食品とすることができる。 The food composition for promoting melatonin production and the food composition for improving sleep quality of the present invention can be suitably used as foods with functional claims and foods for specified health uses based on the above-mentioned functionality and useful effects on the living body. it can.
以下に実施例を挙げて本発明を詳細に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited to these examples.
事前アンケートで自身の睡眠に不満をもつと回答した３０歳以上７０歳未満の健常成人男女１６名を対象とし、以下の実施例１の試験食品又は比較例１のプラセボ食品を４週間摂取させて、二重盲検プラセボ対照並行群間比較試験を実施した。 Sixteen healthy adult men and women between the ages of 30 and 70 who answered that they were dissatisfied with their sleep in the pre-questionnaire were given the following test food of Example 1 or placebo food of Comparative Example 1 for 4 weeks. , A double-blind, placebo-controlled, parallel-group comparative study was conducted.
＜実施例１＞
試験食品として、ブロッコリースプラウト由来のグルコラファニンを含有するカプセル剤（３粒中にグルコラファニン３１．３ｍｇ）を用いた（スルフォラファン摂取群）。試験食品は、摂取期間中１日１回３粒を約１００ｍＬの水又は白湯とともに毎日摂取するよう、研究対象者に説明した。
<Example 1>
As a test food, a capsule containing glucoraphanin derived from broccoli sprout (31.3 mg of glucoraphanin in 3 capsules) was used (sulforaphane intake group). The study subjects were instructed to take 3 tablets of the test food once daily with about 100 mL of water or plain hot water during the ingestion period.
＜比較例１＞
プラセボ食品として、グルコラファニン及びスルフォラファンを含まないカプセル剤を使用した（プラセボ摂取群）。
<Comparative example 1>
As a placebo food, capsules free of glucoraphanin and sulforaphane were used (placebo intake group).
＜試験例１＞
実施例の１試験食品及び比較例１のプラセボ食品の摂取前と４週間摂取後に各々２１時、２３時、翌朝７時から８時の間、の３点でそれぞれ４ｍＬの唾液を採取して、マイナス８０℃で保管した。採種した唾液サンプルを解凍後、Ｓａｌｉｖａｒｙ Ｍｅｌａｔｏｎｉｎ Ｅｎｚｙｍｅ Ｉｍｍｕｎｏａｓｓａｙ Ｋｉｔ（Ｓａｌｉｍｅｔｒｉｃｓ社）を用いて、取扱説明書に記載のとおり、ＥＬＩＳＡ法により唾液中のメラトニン量を測定した（図１）。また、摂取前後における、各時間でのメラトニン量からＡＵＣ値（Ａｒｅａ Ｕｎｄｅｒ ｔｈｅ Ｃｕｒｖｅ：曲線下面積値）の評価を行い、平均値の比較と、Ｗｉｌｃｏｘｏｎ符号付順位和検定による解析を行った（図２）。
<Test Example 1>
Before and after ingesting the placebo food of Example 1 and Comparative Example 1, 4 mL of saliva was collected at 3 points, 21:00, 23:00, and 7:00 to 8:00 the next morning, respectively, and minus 80. Stored at ° C. After thawing the collected saliva sample, the amount of melatonin in saliva was measured by the ELISA method using a Salivary Melatonin Enzyme Immunoassay Kit (Salimetrics) as described in the instruction manual (FIG. 1). In addition, the AUC value (Area Under the Curve) was evaluated from the amount of melatonin at each time before and after ingestion, the average value was compared, and the Wilcoxon signed rank sum test was used for analysis (Fig.). 2).
＜試験例２＞
睡眠の質について、ビジュアル・アナログ・スケール（ＶＡＳ）法を用いて評価を行った。ＶＡＳ法とは、両端に対をなす極端な状態を表記した長さ１００ｍｍの線分上に、被験者自身に記入時の主観的な感覚を垂直な１本線で表してもらい、端からその垂線までの長さを測定してＶＡＳスコアとすることで、被験者の主観的な感覚を評価する方法である。今回の評価では、「睡眠の質」の左端を「昨晩の睡眠の質は非常に悪かった」としてスコア０とし、右端を「昨晩の睡眠の質は非常に良かった」としてスコア１０とした。つまり、数字が大きいほど、良い評価となる。ＶＡＳ法の評価結果は、摂取開始前と１、２、４週間摂取後について、２元配置分散分析後、Ｄｕｎｎｅｔ検定（ｖｓ ０週）により解析した（図３）。
<Test Example 2>
The quality of sleep was evaluated using the visual analog scale (VAS) method. The VAS method is a line segment with a length of 100 mm that indicates an extreme state paired at both ends, and the subject himself / herself is asked to express the subjective sensation at the time of writing with a single vertical line, from the end to the perpendicular line. It is a method of evaluating the subjective sensation of a subject by measuring the length of the subject and using it as a VAS score. In this evaluation, the left end of "sleep quality" was given a score of 0 as "last night's sleep quality was very poor", and the right end was given a score of 10 as "last night's sleep quality was very good". In other words, the larger the number, the better the evaluation. The evaluation results of the VAS method were analyzed by Dunnett's test (vs 0 week) after the two-way ANOVA before the start of ingestion and after 1, 2 and 4 weeks of ingestion (Fig. 3).
＜評価結果＞
試験例１において、スルフォラファン摂取群（実施例１）では、唾液中のメラトニン量が、摂取前と比較して摂取後の２１時の測定ポイントで有意な高値を示した。プラセボ摂取群（比較例１）では摂取前後で有意な差はなく、実測値・変化量ともに群間での差は確認されなかった（図１）。また、ＡＵＣにおいて、スルフォラファン摂取群では、摂取前と比較して摂取後で有意な高値を示した。プラセボ摂取群では摂取前後で有意な差はなく、実測値・変化量ともに群間での差は確認されなかった（図２）。したがって、スルフォラファンはメラトニン量の増加を引き起こすこと、つまり、メラトニンの産生を促進していることが示された。
<Evaluation result>
In Test Example 1, in the sulforaphane ingestion group (Example 1), the amount of melatonin in saliva showed a significantly higher value at the measurement point at 21:00 after ingestion as compared with before ingestion. In the placebo intake group (Comparative Example 1), there was no significant difference before and after ingestion, and no difference was confirmed between the groups in terms of measured value and amount of change (Fig. 1). In addition, in the AUC, in the sulforaphane ingestion group, a significantly higher value was shown after ingestion as compared with before ingestion. There was no significant difference between the placebo intake group before and after ingestion, and no difference was confirmed between the groups in terms of measured value and amount of change (Fig. 2). Therefore, it was shown that sulforaphane causes an increase in the amount of melatonin, that is, promotes the production of melatonin.
試験例２において、スルフォラファン摂取群のＶＡＳ値は、試験食品摂取前と比較して、試験食品摂取２、４週目で有意な高値を示した（図３）。一方、プラセボ摂取群では、有意な変化はなかった。したがって、スルフォラファン摂取による睡眠の質の改善効果が示唆された。 In Test Example 2, the VAS value of the sulforaphane intake group was significantly higher at the 2nd and 4th weeks of the test food intake than before the test food intake (Fig. 3). On the other hand, there was no significant change in the placebo intake group. Therefore, it was suggested that the intake of sulforaphane improved the quality of sleep.
本発明が有用な分野は、医薬品、栄養補助食品及び機能性表示食品である。 Areas in which the present invention is useful are pharmaceuticals, dietary supplements and foods with functional claims.
Claims (16)
その有効成分は、グルコラファニン及びスルフォラファンの少なくとも一種である。 A melatonin production promoter
Its active ingredient is at least one of glucoraphanin and sulforaphane.
前記グルコラファニン及びスルフォラファンは、アブラナ科植物由来である。 The melatonin production promoter according to claim 1.
The glucoraphanin and sulforaphane are derived from cruciferous plants.
前記アブラナ科植物は、ブロッコリーである。 The melatonin production promoter according to claim 1 or 2.
The cruciferous plant is broccoli.
それが含有するのは、ブロッコリースプラウト抽出物である。 The melatonin production promoter according to any one of claims 1 to 3.
It contains a broccoli sprout extract.
グルコラファニン及びスルフォラファンの少なくとも一種である。 A food composition for promoting melatonin production, which contains at least,
It is at least one of glucoraphanin and sulforaphane.
前記グルコラファニン及びスルフォラファンは、アブラナ科植物由来である。 The food composition for promoting melatonin production according to claim 5.
The glucoraphanin and sulforaphane are derived from cruciferous plants.
前記アブラナ科植物は、ブロッコリーである。 The food composition for promoting melatonin production according to claim 5 or 6.
The cruciferous plant is broccoli.
それが含有するのは、ブロッコリースプラウト抽出物である。 A food composition for promoting melatonin production according to any one of claims 5 to 7.
It contains a broccoli sprout extract.
その有効成分は、グルコラファニン及びスルフォラファンの少なくとも一種である。 It ’s a sleep quality improver,
Its active ingredient is at least one of glucoraphanin and sulforaphane.
前記グルコラファニン及びスルフォラファンは、アブラナ科植物由来である。 The sleep quality improving agent according to claim 9.
The glucoraphanin and sulforaphane are derived from cruciferous plants.
前記グルコラファニン及びスルフォラファンは、ブロッコリースプラウト由来である。 The sleep quality improving agent according to claim 9 or 10.
The glucoraphanin and sulforaphane are derived from broccoli sprout.
それが含有するのは、ブロッコリースプラウト抽出物である。 A sleep quality improving agent according to any one of claims 9 to 11.
It contains a broccoli sprout extract.
グルコラファニン及びスルフォラファンの少なくとも一種である。 A food composition for improving sleep quality that contains, at least,
It is at least one of glucoraphanin and sulforaphane.
前記グルコラファニン及びスルフォラファンは、アブラナ科植物由来である。 The food composition for improving sleep quality according to claim 13.
The glucoraphanin and sulforaphane are derived from cruciferous plants.
前記アブラナ科植物は、ブロッコリーである。 The food composition for improving sleep quality according to claim 13 or 14.
The cruciferous plant is broccoli.
それが含有するのは、ブロッコリースプラウト抽出物である。 A food composition for improving sleep quality according to any one of claims 13 to 15.
It contains a broccoli sprout extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019175044A JP7499013B2 (en) | 2019-09-26 | 2019-09-26 | Melatonin production promoter and sleep quality improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019175044A JP7499013B2 (en) | 2019-09-26 | 2019-09-26 | Melatonin production promoter and sleep quality improver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021048806A true JP2021048806A (en) | 2021-04-01 |
| JP7499013B2 JP7499013B2 (en) | 2024-06-13 |
Family
ID=75154807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019175044A Active JP7499013B2 (en) | 2019-09-26 | 2019-09-26 | Melatonin production promoter and sleep quality improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7499013B2 (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003335691A (en) * | 2002-05-20 | 2003-11-25 | Fancl Corp | Agent for treatment of melatonin-relating disease |
| JP2004043378A (en) * | 2002-07-12 | 2004-02-12 | Fancl Corp | Luteinizing hormone-releasing hormone-like substance |
| JP2006109754A (en) * | 2004-10-14 | 2006-04-27 | Redox Bioscience Inc | Food inducing expression of thioredoxin |
| CN102526217A (en) * | 2011-10-13 | 2012-07-04 | 宁波海逸生物科技有限公司 | Formula of health-care medicine with functions of strengthening immunity and promoting sleep |
| CN104187295A (en) * | 2014-07-22 | 2014-12-10 | 当涂县龙山桥粮油工贸有限公司 | Healthcare rice calming nerves and helping sleep and preparing method thereof |
| WO2015163443A1 (en) * | 2014-04-25 | 2015-10-29 | ヤクルトヘルスフーズ株式会社 | Agent for delaying appearance of physical symptoms associated with aging |
| CN106473137A (en) * | 2016-09-23 | 2017-03-08 | 惠安县科联农业科技有限公司 | A kind of have food formula improving insomnia and preparation method thereof |
| CN109479689A (en) * | 2018-12-14 | 2019-03-19 | 扬州大学 | A kind of epiphysin efficiently concentrating method in Vegetables in Brassica sprout |
| CN109588698A (en) * | 2017-09-30 | 2019-04-09 | 华中科技大学 | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method |
| KR20190068389A (en) * | 2017-12-08 | 2019-06-18 | 주식회사 아미코스메틱 | A cosmetic composition comprising cabbage cultiva rfermented extract |
-
2019
- 2019-09-26 JP JP2019175044A patent/JP7499013B2/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003335691A (en) * | 2002-05-20 | 2003-11-25 | Fancl Corp | Agent for treatment of melatonin-relating disease |
| JP2004043378A (en) * | 2002-07-12 | 2004-02-12 | Fancl Corp | Luteinizing hormone-releasing hormone-like substance |
| JP2006109754A (en) * | 2004-10-14 | 2006-04-27 | Redox Bioscience Inc | Food inducing expression of thioredoxin |
| CN102526217A (en) * | 2011-10-13 | 2012-07-04 | 宁波海逸生物科技有限公司 | Formula of health-care medicine with functions of strengthening immunity and promoting sleep |
| WO2015163443A1 (en) * | 2014-04-25 | 2015-10-29 | ヤクルトヘルスフーズ株式会社 | Agent for delaying appearance of physical symptoms associated with aging |
| CN104187295A (en) * | 2014-07-22 | 2014-12-10 | 当涂县龙山桥粮油工贸有限公司 | Healthcare rice calming nerves and helping sleep and preparing method thereof |
| CN106473137A (en) * | 2016-09-23 | 2017-03-08 | 惠安县科联农业科技有限公司 | A kind of have food formula improving insomnia and preparation method thereof |
| CN109588698A (en) * | 2017-09-30 | 2019-04-09 | 华中科技大学 | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method |
| KR20190068389A (en) * | 2017-12-08 | 2019-06-18 | 주식회사 아미코스메틱 | A cosmetic composition comprising cabbage cultiva rfermented extract |
| CN109479689A (en) * | 2018-12-14 | 2019-03-19 | 扬州大学 | A kind of epiphysin efficiently concentrating method in Vegetables in Brassica sprout |
Non-Patent Citations (1)
| Title |
|---|
| 青木雄大ほか: "ブロッコリースプラウト抽出物が睡眠に与える影響の探索", NEW DIET THERAPY, vol. 35, no. 2, JPN6022053439, 2019, pages 174, ISSN: 0005088700 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7499013B2 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020012819A2 (en) | flavored articles that have a low ph | |
| KR102456356B1 (en) | Composition for relieving premenstrual syndrome comprising mixture of lactobacillus strains as an active ingredient | |
| AU2024216546A1 (en) | Kaempferol analog-containing composition | |
| US20090269424A1 (en) | Peripheral blood flow-improving composition | |
| JP2010265251A (en) | Bloodstream-promoting/improving agent | |
| JP2014091720A (en) | Blood flow promoting agent | |
| JP6773361B2 (en) | Mood condition improver | |
| KR20200101113A (en) | A composition for improving, preventing and treating dermatitis comprising Chrysanthemum zawadskii var extract | |
| JP2003055244A (en) | Agent promoting hyaluronic acid production, cosmetics, food and beverage including the hyaluronic acid production-promoting agent | |
| KR102524364B1 (en) | Composition for preventing or treating periodontitis comprising cannabidiol and taurine | |
| JP7499013B2 (en) | Melatonin production promoter and sleep quality improver | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR102481095B1 (en) | Inner beauty composition for anti-wrinkle containing red sea cucumber and fish collagen | |
| JP7136939B2 (en) | Composition for improving vascular endothelial function | |
| US20080020067A1 (en) | Skin Moisturizer | |
| JP2007204419A (en) | Food composition | |
| JP7162917B2 (en) | heart rate reducing agent | |
| KR20130119424A (en) | Ingredients derived from sphaeranthus indicus | |
| JP4669077B1 (en) | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient | |
| JP7405543B2 (en) | Oral skin care composition | |
| JP2007031297A (en) | Skin-beautifying composition | |
| JP6888145B2 (en) | LPS production inhibitor and food composition for suppressing LPS production | |
| JP7433125B2 (en) | Oral antibacterial agent | |
| EP4449889A1 (en) | Composition for improving sleep quality or controlling autonomic nervous system | |
| JP7371851B2 (en) | Composition containing oleanane-type triterpene that prevents or improves physical fatigue and feeling of fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190926 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230621 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231102 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240312 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240528 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240603 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7499013 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |